SK CDM-QIP Diabetes + CAD Flow Sheet

Type of Diabetes: Type 1 Type 2 Other		Patient Name:					
Date [Diagnosed/Duration of DM:						
CAD History and Interventions:				Date of Birth:			
	or ACS date						
	gina date	_					
	/Angioplasty + stent date			HSN:			
	3G date						
Como	rbidities: 🗆 Hypertension 🛛 HF 🗆 A	F 🗆 CVA 🗆 PAD 🗆 OSA 🗆	CKD stag	ge 🗆 Mental Hea	alth Conditio	n 🗆 Other	
		Date:	Date:		Date:		
Subje	ctive						
	A1c (target ≤ 7% or)	Result Test Date	Result	Test Date	Result	Test Date	
	Glycemic Therapy/Medications						
¥	Adherence/concerns						
mer							
age	Review glucose records						
Man							
nic I	Hypoglycemic episodes						
Glycemic Management	Consider frequency, severity; provide educational resources						
ΰ	DM and driving discussed						
	SGI medical reporting form if using insulin						
	Contraception/preconception advice for women						
	Sick day management reviewed						
	Consider SADMANS, other patient handouts						
~	Any CAD/PAD/HF symptoms						
Cardiac History & Stability	(angina/MI symptoms, palpitations, exertional dyspnea, change in exercise tolerance, HF symptoms, edema,						
	claudication, nitroglycerin use) Change in functional status or new						
	-						
s a	CV complications						
	CV complications						
<u> </u>	Is patient experiencing low	☐ Yes ☐ No ☐ Not asked	□ Yes	□ No □ Not asked	□ Yes □ N	lo 🗌 Not asked	
social	Is patient experiencing low mood/anhedonia/anxiety?	☐ Yes ☐ No ☐ Not asked	□ Yes	□ No □ Not asked	☐ Yes ☐ N	lo 🗌 Not asked	
Psychosocial review	Is patient experiencing low	Yes No Not asked	☐ Yes	□ No □ Not asked	Yes 🗆 N	lo 🗆 Not asked	







SK CDM-QIP Diabetes + CAD Flow Sheet

		Date:	Date:	Date:
	Nutrition/Diet review			
Lifestyle	Physical activity (Reduce sedentary time, aerobic plus resistance exercise)			
	Smoking status	□ Non-smoker □ Ex-smoker □ Smoker	□ Non-smoker □ Ex-smoker □ Smoker	□ Non-smoker □ Ex-smoker □ Smoker
	Smoking cessation advice (if required)	🗆 Yes 🛛 No	🗆 Yes 🛛 No	🗆 Yes 🛛 No
CVD Investigations	ECG (Consider if CVD symptoms; q 1-2 years if stable)	□ Ordered today □ Up to date	Ordered today Up to date	Ordered today Up to date
	Other – Echo, Angiogram, Nuclear Med Perfusion Scan			
9	Lipid profile – LDL, non-HDL	Result Test Date	Result Test Date	Result Test Date
Û	(Primary target: LDL < 2.0 mmol/L or >50% reduction with treatment; non-HDL < 2.6 mmol/L)			
~	Serum creatinine	Non-HDL Result Test Date	Non-HDL Result Test Date	Non-HDL Result Test Date
Nephropathy	eGFR (normal > 60ml/min)	Result Test Date	Result Test Date	Result Test Date
Neph	Nephropathy (Abnormal ACR, eGFR on ≥ 2 tests in 3 months)	□ Yes □ No	🗆 Yes 🛛 No	🗆 Yes 🛛 No
Retinopathy	Dilated eye exam (type 1 annually, type 2 q1-2 years)			
	Retinopathy	🗆 Yes 🛛 No	🗆 Yes 🛛 No	□ Yes □ No
Retin	Severity/comments			
Neuropathy	Symptoms (Paresthesia/pain/numbness, GI symptoms, ED, diabetic foot complications)			
Neur	Diabetic foot exam done today Record details in exam section	□ Yes □ No	□ Yes □ No	□ Yes □ No
	Peripheral neuropathy	🗆 Yes 🛛 No	🗆 Yes 🛛 No	🗆 Yes 🛛 No
	Weight (kg)			
Physical exam	BP (target 130/80)			
	Heart rate/rhythm			
	Diabetic foot exam			
	Other exam findings			
Vaccines	Vaccines reviewed Details/comments (Check EHR viewer for vaccine status)			







SK CDM-QIP Diabetes + CAD Flow Sheet

		Date:	Date:	Date:
	Statin (Indicated in all people with CAD+DM unless contraindicated or documented adverse effects; then consider other lipid-lowering agents)	Indicated: Continue Start St	Indicated: Continue Start No - not appropriate No - not tolerated No - indicated, declined No - unable to afford	Indicated: Continue Star No - not appropriate No - not tolerated No - indicated, declined No - unable to afford
	ACEI/ARB (ACE inhibitor or ARB indicated indefinitely unless contraindicated)	Indicated: Continue Start Sta	Indicated: Continue Start No - not appropriate No - not tolerated No - indicated, declined No - unable to afford	Indicated: Continue Star No - not appropriate No - not tolerated No - indicated, declined No - unable to afford
CVD medications	Beta blocker (Indicated for all patients with normal LV function for minimum 3 years following ACS/MI unless contraindicated; specific beta-blockers recommended if reduced LVEF with prior MI or heart failure)	Indicated: Continue Start Sta	Indicated: Continue Start No - not appropriate No - not tolerated No - indicated, declined No - unable to afford	Indicated: Continue Star No - not appropriate No - not tolerated No - indicated, declined No - unable to afford
CVD m	Consider SGLT2i and/or GLP1a - for cardiorenal benefit independent of			
	glycemic control Antiplatelet agent (Low-dose ASA indefinitely unless OAC indicated; dual antiplatelet therapy (DAPT) recommended for minimum 12 months after ACS and/or PCI)	□ ASA □ Clopidogrel □ Other	□ ASA □ Clopidogrel □ Other	ASA Clopidogrel Other
	Review DAPT indication/ongoing use	□ N/A □ Done	□ N/A □ Done	□ N/A □ Done
	CV medication adherence/comments/notes			
	Patient goals/self-management			
	Advance care planning (Discuss as needed; provide resources)			
_	Referrals for education/nutrition/exercise			
ent Plan	Referrals to medical specialists			
Manageme	Assessment and management plan (Changes to medications, resources provided to patient, etc.)			
	For CDM QIP online resources/hand			





CDMQIP Paper Flowsheet